Although this study highlighted how exosomal CA-125 may be used to distinguish between healthy controls and cancer patients (Zhao et al., 2016), the associated drawbacks of CA-125 as a promising ovarian cancer biomarker for early detection remain a challenge. This evidence concerns the gene MUC16 and ovarian carcinoma.